Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot randomized double-blind trial of lipid reduction in parenteral nutrition–associated liver dysfunction
2014-003597-17Phase 4Active
- Sponsor
- Josep Llop Talaveron
- Start
- Oct 2014
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of eicosapentaenoic acid, docosahexaenoic acid and soybean oil emulsion in intestinal failure-associated liver disease (IFALD), cholestatic disease and disorder of nutritional metabolism (2 arms), sponsored by Josep Llop Talaveron. Primary endpoints: Phytosterolemia levels after lipid reduction and Liver function parameters. Started Oct 2014; status: active.
02
Drugs
eicosapentaenoic aciddocosahexaenoic acidsoybean oil emulsion
03
Conditions
intestinal failure-associated liver disease (IFALD)cholestatic diseasedisorder of nutritional metabolism
Beyond the preview
Go deeper on 2014-003597-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003597-17.